• Vaccine Name: Infectious Salmon Anemia Virus Inactivated Vaccine
• Target Pathogen: Infectious salmon anemia virus
• Target Disease: Infectious Salmon Anemia
• Type: Inactivated or "killed" vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: ISAV isolate Bremnes 98 (Lauscher et al., 2011)
• Preparation: The vaccine antigen was produced as lysates of ISAV- infected SHK-1 cells inactivated by 0.1% formalin at 4°C for 7 days. The vaccine was formulated as a water-in-oil emulsion using MontanideTM ISA 763A (Seppic) with an adjuvant/antigen ratio of 70/30 (weight/weight). (Lauscher et al., 2011)
• Immunization Route: Intraperitoneal injection (i.p.)
• Description: Inactivated ISAV vaccine with high antigen dose is able to induce protective efficacy in Atlantic salmon. (Lauscher et al., 2011)

Fish Response

• Vaccination Protocol: The fish were randomly picked from a reservoir population (n > 1500) and vaccinated group by group as they came by hand (60 fish per group in tank I and 90 fish per group in tank II). Groups 1–3 were immunized with the vaccine ISAV 100%, 20% and 4%, respectively, while fish in groups 4 and 5 were injected with mock vaccine (adjuvant control) and physiological saline, respectively. One dose was 0.1 ml, given by intraperitoneal (i.p.) injection. (Lauscher et al., 2011)
• Immune Response: The numbers of ISAV- antibodies positive fish were significantly higher (p < 0.001) in the group ISAV 100% than in the group ISAV 20% at all samplings. ISAV-specific antibodies were not detected by ELISA in any of the eight control fish sampled prior to vaccination. (Lauscher et al., 2011)
• Challenge Protocol: Six weeks post vaccination (wpv), 49 and 50 “shedder” fish infected i.p. with 0.1 ml ISAV of a Chilean field isolate i.e., approximately 3 × 10^6 TCID50 /fish, were placed into tanks I and II, respectively. (Lauscher et al., 2011)
• Efficacy: The mortality curve of the group injected with saline was almost identical with that of the group adjuvant control, and on 45 dpc the cumulative mortalities were 71.7% and 63.3% for these groups, respectively. The vaccinated groups showed declining cumulative mortality with increasing amounts of ISAV antigen, with 55.0% for ISAV 4%, 28.3% for ISAV 20% and 10.0% for ISAV 100%. The cumulative mortality was significant lower in group ISAV 100% than in group ISAV 20% (p<0.02) and highly significant lower than in all other groups (p < 0.001). (Lauscher et al., 2011)